Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 2, 2003, Pages 328-334

  Wang, Xiaoling ^a,b   Fan, Zhongjie ^b,c   Huang, Jianfeng ^a   Su, Shaoyong ^a   Yu, Quanjun ^a   Zhao, Jiangong ^a   Hui, Rutai ^a   Yao, Zhijian ^a,b   Shen, Yan ^b   Qiang, Boqin ^b   Gu, Dongfeng ^a,b  

^a FUWAI HOSPITAL   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Coronary heart disease; Genetics; LDL oxidation; Linkage disequilibrium; Paraoxonase

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE; GENE CLUSTER; GENE FREQUENCY; HAPLOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PON GENE; PRIORITY JOURNAL;

ALLELES; ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CORONARY DISEASE; ESTERASES; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIGENE FAMILY; POLYMORPHISM, GENETIC;

EID: 0037324353     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000051702.38086.C1     Document Type: Article

References (26)

1. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
2. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high-density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest. 1995;96:2882-2891.
3. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism. J Lipid Res. 1999;40:133-139.
4. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonse/arylesterase gene is one member of a multigene family. Genomics. 1996;33:498-507.
5. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM. Human Paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol. 2001;21:542-547.
6. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem. 2001;276:44444-44449.
7. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/aryiesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;3:73-76.
8. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet. 1997;349:851-852.
9. Leviev I, Franco N, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol. 1997;17:2935-2939.
10. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20:516-521.
11. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K. A polymorphism upstream from the human paraoxonase gene and its association with PON1 expression. Atherosclerosis. 2000;150:295-298.
12. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene(PON1) expression. Am J Hum Genet. 2001;68: 1428-1436.
13. Hegele RA, Harris SB, Connelly PW, Hanley AJ, Tsui LC, Zinman B, Scherer SW. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin Genet. 1998; 54:394-399.
14. Hegele RA, Connelly PW, Scherer SW. Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with the elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:3373-3377.
15. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Arg 192 polymerphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995; 346:869-872.
16. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest. 1996;98:883-885.
17. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17:3565-3569.
18. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase gene (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62:36-44.
19. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21:1451-1457.
20. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. Journal of Molecular Medicine. 2001;79:457-463.
21. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes. 2000;49: 1390-1393.
22. Ray A. A SAF binding site in the promoter region of humanγ-fibrinogen gene functions as an IL-6 response element. J Immunol. 2000;165: 3411-3417.
23. Van Lenten BJ, Wagner AC, Navab M. Fogelman AM. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem. 2001; 276:1923-1929.
24. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97:10483-10488.
25. Hoehe MR, Köpke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM. Sequence variability and candidate gene analysis in complex disease: association of μ opioid receptor gene variation with substance dependence. Hum Mol Genet. 2000;9:2895-2908.
26. Davidson S. Research suggests importance of haplotypes over SNPs. Nat Biotechnol. 2000;18:1134-1135.